News

anticoagulation therapy, pulmonary embolism, Couturaud, discontinuation

Among patients with a first episode of pulmonary embolism who received six months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the risk of additional...

The Medicines Company, Angiomax, generic launch, Sandoz Inc.

The Medicines Company announced an agreement July 9 with Sandoz Inc. for the distribution of an authorized generic of Angiomax (bivalirudin) for injection in the United States.

The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.

The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company in its bivalirudin (Angiomax) patent litigation with Hospira Inc.

Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE

Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to discharge patients experiencing a potentially fatal blood clot....

platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury...

idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD

Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab immediately reversed the anticoagulant effect of dabigatran (Pradaxa) in patients...

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent

The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary...

Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events with an additional 18 months of dual antiplatelet therapy rather than placebo,...

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results

AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose aspirin, at the American College of...

rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015

Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI

Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilostazol prior to a surgical procedure safely transitioned off of dual antiplatelet therapy (...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI

Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results...

A new study reports that antiplatelet drug ticagrelor (Brilinta) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart...

One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called pulmonary embolism, PE) or in the legs (also known as deep vein thrombosis, DVT...

Brilinta, AstraZeneca, FDA, sNDA, PEGASUS-TIMI 54, new indication

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets for...

The Medicines Company, cangrelor, FDA advisory committee, approval

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9 - 2 with one abstention to recommend approval of...

The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals...

ticagrelor, AstraZeneca, FDA, crushing, option

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow ticagrelor (...